Current clinical evidence supports the use of aspirin for secondary prevention of cardiovascular disease in diabetic populations and for primary prevention of cardiovascular disease in diabetic populations at high risk for cardiovascular disease. The recommended uses of antiplatelet therapy are: ① Aspirin should be routinely used as secondary prevention in diabetic patients with a history of cardiovascular disease. A. Patients at high cardiovascular risk (10-year cardiovascular risk >10%): Most men >50 years of age or women >60 years of age with a combination of one risk factor (family history of cardiovascular disease, hypertension, smoking, dyslipidemia, or proteinuria), without significant bleeding risk (previous history of gastrointestinal bleeding, gastric ulcer or recent use of drugs that increase the risk of bleeding, such as non-steroidal anti-inflammatory drugs or warfarin) can take small doses of aspirin as primary prevention. B. Young and middle-aged people with moderate cardiovascular risk, with one or more cardiovascular disease risk factors (men <50 years or women ③ For long-term use, the optimal dose of aspirin is 75-150 mg/d. In short, aspirin therapy for diabetic patients4 The main points are: 1. secondary prevention routine use; 2. diabetic men > 50 years old or women > 60 years old can take; 3. diabetic patients with cardiovascular risk can take; 4. risk of bleeding people with caution. For those who cannot tolerate aspirin, clopidogrel can be used instead.